Variant · Amplification
CCND1 Amplification
CI-VAR-00000198Explore in graph →CIViC 18
Curated evidence
Evidence by cancer (9 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26307133
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Cutaneous Melanoma1 | ||||||||
| CCND1 Amplification | Carboplatin + Paclitaxel + SorafenibCombination | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1495Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved … (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC | civic |
| Lung Non-Small Cell Carcinoma1 | ||||||||
| CCND1 Amplification | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID354Inceased copy number of CCND1 is associated with poorer overall survival. PMID · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available